Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 13/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 11/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.66 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.66 |
| ▸ | LMNA | P02545 | 2/20 | 0.66 |
| ▸ | CTSB | P07858 | 2/20 | 0.66 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.66 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.66 |
| ▸ | HTT | P42858 | 2/20 | 0.66 |
| ▸ | NPC1 | O15118 | 1/20 | 0.66 |
| ▸ | BRD4 | O60885 | 1/20 | 0.66 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.66 |
| ▸ | DRD2 | P14416 | 1/20 | 0.66 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.66 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.66 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.66 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.66 |
| ▸ | HTR2C | P28335 | 1/20 | 0.66 |
| ▸ | CTH | P32929 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18113456 | 0.88 | MAPT (0.66) | MAPTALDH1A1KDM4ESMN1; SMN2TDP1 | |
| SCHEMBL3128062 | 0.83 | MAPT (0.59) | MAPTALDH1A1KDM4ESMN1; SMN2TDP1 | |
| SCHEMBL69673 | 0.80 | KDM4E (0.77) | MAPTALDH1A1KDM4ESMN1; SMN2TDP1 | |
| Nitroxoline SCHEMBL29363027 | 0.80 | MAPT (1.00) | MAPTALDH1A1KDM4ESMN1; SMN2TDP1 | |
| Nitroxoline SCHEMBL151248 | 0.80 | MAPT (1.00) | MAPTALDH1A1KDM4ESMN1; SMN2TDP1 | |
| SCHEMBL8441763 | 0.79 | MAPT (0.54) | MAPTALDH1A1KDM4ESMN1; SMN2TDP1 | |
| SCHEMBL28138024 | 0.78 | MAPT (0.64) | MAPTALDH1A1KDM4ESMN1; SMN2TDP1 | |
| SCHEMBL6974167 | 0.78 | JMJD7 (0.63) | MAPTALDH1A1KDM4ESMN1; SMN2TDP1 | |
| Nitroxoline SCHEMBL17474134 | 0.78 | MAPT (0.97) | MAPTALDH1A1KDM4ESMN1; SMN2TDP1 | |
| Nitroxoline SCHEMBL16062144 | 0.78 | MAPT (0.97) | MAPTALDH1A1KDM4ESMN1; SMN2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250223299-A1 | MAYTANSINOID DERIVATIVES, CONJUGATES THEREOF, AND METHODS OF USE | REGENERON PHARMACEUTICALS, INC. | 2025-07-10 | — | — | US | disclosed |
| US-12297207-B2 | Maytansinoid derivatives, conjugates thereof, and methods of use | REGENERON PHARMACEUTICALS, INC. (US) | 2025-05-13 | — | — | US | disclosed |
| CN-116507333-B | Cyclic AMP response element binding protein (CBP) and/or 300KDA adenovirus E1A binding protein (P300) degrading compounds and methods of use | 上海睿跃生物科技有限公司 | 2025-05-09 | — | — | CN | disclosed |
| US-12234220-B2 | Immunomodulatory compounds | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2025-02-25 | — | — | US | disclosed |
| US-20240100170-A1 | CYCLIC-AMP RESPONSE ELEMENT BINDING PROTEIN (CBP) AND/OR ADENOVIRAL E1A BINDING PROTEIN OF 300 KDA (P300) DEGRADATION COMPOUNDS AND METHODS OF USE | CULLGEN (SHANGHAI) , INC. (CN) | 2024-03-28 | — | — | US | disclosed |
| CN-110997627-B | Cyst amide derivatives | 亥姆霍兹感染研究中心有限公司 | 2023-10-10 | — | — | CN | disclosed |
| CN-116507333-A | Cyclic AMP response element binding protein (CBP) and/or 300KDA adenovirus E1A binding protein (P300) degrading compounds and methods of use | 上海睿跃生物科技有限公司 | 2023-07-28 | — | — | CN | disclosed |
| CN-115645543-A | Maytansinoid derivatives, conjugates thereof, and methods of use | 里珍纳龙药品有限公司 | 2023-01-31 | — | — | CN | disclosed |
| US-20220259225-A1 | Maytansinoid Derivatives, Conjugates Thereof, and Methods of Use | REGENERON PHARMACEUTICALS, INC. | 2022-08-18 | — | — | US | disclosed |
| WO-2022042707-A1 | CYCLIC-AMP RESPONSE ELEMENT BINDING PROTEIN (CBP) AND/OR ADENOVIRAL E1A BINDING PROTEIN OF 300 KDA (P300) DEGRADATION COMPOUNDS AND METHODS OF USE | CULLGEN (SHANGHAI) , INC. (CN) | 2022-03-03 | — | — | WO | disclosed |
| WO-2003096980-A2 | BICYCLIC MODULATORS OF ANDROGEN RECEPTOR FUNCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-11-27 | — | — | WO | disclosed |
| EP-0931070-B1 | HETAROYL CYCLOHEXANEDIONE DERIVATIVES WITH HERBICIDAL EFFECT | BASF AG (DE) | 2003-03-19 | — | — | EP | disclosed |
| US-6479436-B1 | SUCH AS 2-(8-BROMOQUINOLIN-5-YL)CARBONYL-1,3-CYCLOHEXANEDIONE | BASF AKTIENGESELLSCHAFT (DE) | 2002-11-12 | — | — | US | disclosed |
| US-6262074-B1 | 4-Hetaroylpyrazol derivatives and the use thereof as herbicides | BASF AKTIENGESELLSCHAFT (DE) | 2001-07-17 | — | — | US | disclosed |
| CN-1235600-A | 4-hetaroylpyrazol derivatives | BASF AG (DE) | 1999-11-17 | — | — | CN | disclosed |
| CN-1230951-A | Herbicidal heteroaroyl cyclohexanedione derivatives | BASF AG (DE) | 1999-10-06 | — | — | CN | disclosed |
| EP-0931070-A1 | HETAROYL CYCLOHEXANEDIONE DERIVATIVES WITH HERBICIDAL EFFECT | BASF AKTIENGESELLSCHAFT (DE) | 1999-07-28 | — | — | EP | disclosed |
| EP-0929546-A1 | 4-HETAROYLPYRAZOL DERIVATIVES AND THE USE THEREOF AS HERBICIDES | BASF AKTIENGESELLSCHAFT (DE) | 1999-07-21 | — | — | EP | disclosed |
| WO-1998012180-A1 | HETAROYL CYCLOHEXANEDIONE DERIVATIVES WITH HERBICIDAL EFFECT | BASF AKTIENGESELLSCHAFT (DE) | 1998-03-26 | — | — | WO | disclosed |
| WO-1998012192-A1 | 4-HETAROYLPYRAZOL DERIVATIVES AND THE USE THEREOF AS HERBICIDES | BASF AKTIENGESELLSCHAFT (DE) | 1998-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240100170-A1 | CYCLIC-AMP RESPONSE ELEMENT BINDING PROTEIN (CBP) AND/OR ADENOVIRAL E1A BINDING PROTEIN OF 300 KDA (P300) DEGRADATION COMPOUNDS AND METHODS OF USE | CREBBP, EP300, CREB1 | MAPT 3228/4885ALDH1A1 4283/4885KDM4E 1828/4885 |
| US-20250223299-A1 | MAYTANSINOID DERIVATIVES, CONJUGATES THEREOF, AND METHODS OF USE | SLC10A1, HNMT, OGFR | MAPT 3597/4885ALDH1A1 317/4885KDM4E 4593/4885 |
| US-12297207-B2 | Maytansinoid derivatives, conjugates thereof, and methods of use | SLC10A1, HNMT, OGFR | MAPT 3597/4885ALDH1A1 317/4885KDM4E 4593/4885 |
| US-12234220-B2 | Immunomodulatory compounds | CRBN, CD47, CD58 | MAPT 1799/4885ALDH1A1 3939/4885KDM4E 2386/4885 |
| US-20220259225-A1 | Maytansinoid Derivatives, Conjugates Thereof, and Methods of Use | SLC10A1, HNMT, OGFR | MAPT 3597/4885ALDH1A1 317/4885KDM4E 4593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.